# Pharmacist interaction check before every oral cancer-drug prescription

Source: https://onco.cc/ideas/idea-acc-pharmacist-interaction-review-oral-anticancer/  
OnCo record `idea-acc-pharmacist-interaction-review-oral-anticancer` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Oral kinase inhibitors, CDK4/6 inhibitors and hormonal agents interact with proton pump inhibitors, anticoagulants, statins and antiarrhythmics, and are increasingly prescribed to older patients taking all of them. A mandatory oncology pharmacist review at initiation, dose change and refill, with a structured monitoring plan, would catch these interactions systematically.

## Summary

Oral kinase inhibitors, CDK4/6 inhibitors, and hormonal agents have clinically significant interactions with proton pump inhibitors, anticoagulants, statins, and antiarrhythmics, and are increasingly prescribed to older multimorbid patients. Studies find potential interactions in a large proportion of such patients. A mandatory oncology pharmacist review at initiation and dose change, with a structured monitoring plan, would catch these systematically.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Mandatory pharmacist review will reduce clinically significant drug interactions at initiation by at least 70% and reduce interaction-related adverse events and dose interruptions.
- Rationale: Pharmacist review is the established safeguard for intravenous chemotherapy; oral agents escaped it because they are dispensed like ordinary prescriptions.
- Proposed test: A before-and-after study across five centres with interaction rates, adverse events, and dose interruptions as endpoints.
- Maturity: early-clinical
- Actor: clinic

## Sources

- Bottleneck evidence (Older and multimorbid patients are excluded and undertreated): Mohile et al., Evaluation of geriatric assessment and management on toxic effects of cancer treatment (GAP70+, Lancet 2021): https://doi.org/10.1016/S0140-6736(21)01789-X

## Connected records

- ideas: [Structured deprescribing review at cancer diagnosis and again at transition to palliative care](https://onco.cc/ideas/idea-acc-structured-deprescribing-at-diagnosis/)
- technologies: [CDK4/6 inhibitors](https://onco.cc/technologies/cdk46-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/), [Palbociclib](https://onco.cc/drugs/palbociclib/)
- bottlenecks: [Older and multimorbid patients are excluded and undertreated](https://onco.cc/bottlenecks/b-aging-comorbidity/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)

---
JSON: https://onco.cc/api/v1/entities/idea-acc-pharmacist-interaction-review-oral-anticancer.json